US FDA publishes list of drugs undergoing safety scrutiny
This article was originally published in Scrip
Executive Summary
The US FDAhas embarked on a new method for disclosing when marketed drugs are undergoing heightened safety scrutiny by the agency. However, the initiative has raised questions about the scarcity of information released, the potential impact on patient use of medicines, and negative ramifications for product sponsors.